People waiting for medicines have an interest in both timely review and genuine safety scrutiny. FDA’s rule published November 8, 2016 addresses that tension: a qualifying petition does not by itself justify delaying an application. The agency must determine that delay is necessary to protect public health. This November 13 retrospective concerns that earlier rule. [2016-26912][2011-33622]

The January 3, 2012 proposal explained the same safeguard for pending abbreviated new drug applications, used for generics, and applications under the 505(b)(2) pathway. It required a written citizen petition or petition for a stay of action and an FDA public-health determination. That is historical design evidence, not an independent account of how patients fared. [2016-26912][2011-33622]

The final rule, effective January 9, 2017, also addresses qualifying petitions concerning certain biologics applications under section 351(k). Its response language for petitions subject to section 505(q) specifies an intended response within 150 days of receipt, reflecting intervening legislation. The earlier proposal described 180 days. Neither period is a promise that a medicine will be approved or available by then. [2016-26912][2011-33622]

The public-interest distinction is between hearing a concern and automatically letting that concern stop review. The rule preserves a health-based reason for delay while seeking to prevent improper obstruction. These documents belong to the same FDA rulemaking chain, not independent corroboration. They explain the safeguard without demonstrating quicker access, lower prices or the safety of any particular medicine. [2016-26912][2011-33622]

Source documents

  1. Amendments to Regulations on Citizen Petitions, Petitions for Stay of Action, and Submission of Documents to Docketshttps://www.govinfo.gov/content/pkg/FR-2016-11-08/html/2016-26912.htm
  2. Amendments to Regulations on Citizen Petitions, Petitions for Stay of Action, and Submission of Documents to Docketshttps://www.govinfo.gov/content/pkg/FR-2012-01-03/html/2011-33622.htm